Alfresa Profit Jumps on Higher Sales as Outlook Turns Cautious for FY 2027

An announcement from Alfresa Holdings ( (JP:2784) ) is now available.

Alfresa Holdings reported consolidated net sales of ¥3,104.1 billion for the fiscal year ended March 31, 2026, up 4.8% year on year, while operating and ordinary profit declined slightly, and profit attributable to owners of parent surged 52.4% to ¥41.7 billion, lifting basic earnings per share to ¥229.64. The company strengthened its financial position with higher total assets and net assets, increased annual dividends to ¥68 per share, and forecast modest sales growth but lower profits for the year to March 2027, signaling a more conservative earnings outlook despite continued shareholder returns.

Cash flows from operating activities improved significantly to ¥38.6 billion, while investment and financing cash outflows decreased, raising cash and cash equivalents to ¥190.7 billion at year-end. The equity-to-asset ratio edged up to 33.7%, and the company plans a further dividend increase to ¥71 per share next fiscal year, indicating confidence in cash generation even as it guides for a roughly 50% drop in profit attributable to owners of parent due to anticipated margin pressures.

The most recent analyst rating on (JP:2784) stock is a Hold with a Yen2400.00 price target. To see the full list of analyst forecasts on Alfresa Holdings stock, see the JP:2784 Stock Forecast page.

More about Alfresa Holdings

Alfresa Holdings Corporation is a Japan-based healthcare distributor listed on the Tokyo Stock Exchange Prime Market. The group operates primarily in the pharmaceutical wholesaling and related medical distribution businesses, supplying prescription drugs and healthcare products across the domestic market.

Average Trading Volume: 353,006

Technical Sentiment Signal: Buy

Current Market Cap: Yen444.6B

Find detailed analytics on 2784 stock on TipRanks’ Stock Analysis page.